Quick Answer
Hepion Pharmaceuticals, Inc. reported Net Income Loss of -$8.28 million for the year ending 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +37.3% in Net Income Loss from 2024 to 2025.
- This data is from Hepion Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Hepion Pharmaceuticals, Inc.'s Net Income Loss has declined by 56.8%.
- Historical annual values: Fiscal year 2025: -$8.28 million | Fiscal year 2024: -$13.19 million | Fiscal year 2023: -$48.93 million | Fiscal year 2022: -$42.20 million | Fiscal year 2021: -$32.72 million | Fiscal year 2020: -$20.35 million | Fiscal year 2019: -$7.04 million | Fiscal year 2018: -$9.45 million | Fiscal year 2017: -$14.89 million | Fiscal year 2016: -$17.00 million | Fiscal year 2015: -$14.35 million | Fiscal year 2014: -$5.28 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: